Welcome to the 2021 Conference on Dementia

Lorem ipsum proin gravida nibh vel veali quetean sollic lorem quis bibendum nibh vel velit.


Stay Connected & Follow us

Simply enter your keyword and we will help you find what you need.

What are you looking for?

Good things happen when you narrow your focus
Welcome to Conference

Write to us: marko.savic@mbtt.io.

Follow Us

  /  Stanislav Gobec

Stanislav Gobec

Full Professor, Head of the Department of Pharmaceutical Chemistry at the University of Ljubljana Faculty of Pharmacy

Stanislav Gobec, Full Professor at the University of Ljubljana, is one of the groundbreaking researchers in the field of pharmaceutical chemistry in Slovenia. His research work also extends to the field of synthetic chemistry. At the Noli Oblivisci Me 2021 Conference on Dementia, dr. Gobec will present a topis with the title: Process of basic and pre-clinical research for drug discovery in dementia and related diseases.


In recent years, dr. Gobec paid most attention to the structurally supported development of low-molecular-weight inhibitors of therapeutically interesting enzymes. A breakthrough was achieved in the field of covalent chymotrypsin inhibitors of the beta5i immunoproteasome subunit. Dr. Gobec has also been involved in the development of bacterial enzyme inhibitors as potential antibacterial agents. An important role in his work is played by the development of cathepsin B inhibitors, which are involved in the processes of tumor progression.

Full Professor Gobec has also focused his research on the development of cholinergic inhibitors and multifunctional compounds with potential action on Alzheimer’s disease. Professor Gobec enjoys transferring his rich experience to undergraduates and doctoral students at the University Ljubljana Faculty of Pharmacy. Not least, his important achievement is leading and participating in the European research projects

Research Interest

(+) Structure-based, in-silico design, synthesis and evaluation of small-molecule enzyme inhibitors. (+) Agents acting on the central nervous system. (+) Inhibitors of bacterial cell wall biosynthesis. (+) Antitumour agents. (+) Synthesis of mimetics of natural compounds: peptidomimetics, glycomimetics, lipidomimetics.


(+) Drug discovery. (+) Medicinal and pharmaceutical chemistry. (+) In-silico drug design. (+) Virtual high-throughput screening. (+) Organic chemistry. (+) Molecular pharmacology.

Visiting Researcher

  • University of Leeds, 2006.
  • IBBMC, Universite de Paris Sud, 2007.

Member of Editorial and Advisory Boards

  • ACS Infectious Diseases, Advisory Board.
  • Acta Chimica Slovenica, Editorial Board.
  • Molecules, Editorial Board..

Speaking Engagements

  • Joint Meeting on Medicinal Chemistry, Invited Key-Note Speaker.
  • EFMC International Symposium on Medicinal Chemistry.


  • Author or co-author of more than 200 publications in important peer-reviewed journals.
  • Two comprehensive book chapters in Houben-Weyl Science of Synthesis.
  • More than 2.700 pure citations in WoS and 2.900 in SCOPUS.


  • Five granted international patents.
  • Five international patent applications.
  • Seven granted national patents.


(+) Chemical Reviews, (+) Journal of Medicinal Chemistry, (+) Bioorganic and Medicinal Chemistry, (+) Bioorganic and Medicinal Chemistry Letters, (+) Tetrahedron, (+) Tetrahedron Letters, (+) Archiv der Pharmazie, etc.

Teaching courses

(+) Programme Pharmacy (uniform): Pharmaceutical Chemistry III, Design and Synthesis of Active Substances, Nutritional Supplements. (+) Programme Laboratory Biomedicine (1st stage): Introduction to Biomedical Analysis. (+) Programme Industrial Pharmacy (2nd stage): Pharmaceutical Chemistry, Design of New Active Substances. (‘) Programme Biomedicine (3rd stage): Molecular Basis of Medicinal Chemistry (Module 3, Drugs and Their Targets), Design and synthesis of enzyme inhibitors.

Student supervision

(+) Supervisor/mentor for 86 undergraduate student theses in Pharmacy. (+) Supervisor/mentor for 13 PhD theses.

Current Research Grants
Slovenian Research Agency

(+) Two PhD students (65.000 €/y). (+) Project leader: Development of multi-functional compounds for treatment of Alzheimer’s disease (200.000 €).

Slovenia-CEA grant with dr. Jacques Philippe-Colletier

Project leader: Parallel optimisation of inhibitors and imaging probes for butyrylcholinesterase, a validated target for Alzheimer’s disease.

Slovenian-Hungarian project (ARRS-NKFIH) with Prof. Dr. György Miklós Keserű

Project partner: Identification of non-peptidic inhibitors of the immunoproteasome using fragment based drug discovery methods.


  • European Federation for Medicinal Chemistry (EFMC).
  • Association Pomurska akademsko znanstvena unija (PAZU), (Eng: Academic Scientific Union of Pomurje region).

Representative Publications

(+) Košak et al. J. Med. Chem. 2018, 61: 119-139;
(+) Batson et al. Nat. Commun. 2017, 8: 1393;
(+) Sosič et al. Angew. Chem. 2016, 55: 5745-5748;
(+) Sosič et al. J. Med. Chem. 2015, 58: 9712-9721;
(+) Šink et al. J. Med. Chem. 2015, 58: 613-624.

Full Bibliography

All Sessions By Stanislav Gobec

Plenary speech: Process of basic and pre-clinical research for drug discovery in dementia and related diseases
Thursday, September 23rd, 2021 15:00-15:30
Congress Hall